A roadmap for biomarker qualification

A collaborative effort between pharmaceutical companies, regulatory agencies and academia to qualify biomarkers for kidney toxicity provides a model for investigating and identifying reliable safety markers for preclinical applications.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: Receiver operating characteristics (ROC) curve analysis.

References

  1. 1

    Dieterle, F. et al. Nat Biotechnol. 28, 463–469 (2010).

  2. 2

    Yu, Y. et al. Nat. Biotechnol. 28, 470–477 (2010).

  3. 3

    Vaidya, V.S. et al. Nat. Biotechnol. 28, 478–485 (2010).

  4. 4

    Ozer, J.S. et al. Nat. Biotechnol. 28, 486–494 (2010).

  5. 5

    Sistare, F.D. et al. Nat. Biotechnol. 28, 446–454 (2010).

  6. 6

    Dieterle, F. et al. Nat. Biotechnol. 28, 455–462 (2010).

  7. 7

    http://www.fda.gov/oc/initiatives/criticalpath/projectsummary/consortium.html

  8. 8

    http://www.fda.gov/oc/initiatives/criticalpath/

  9. 9

    Bonventre, J.V. et al. Nat. Biotechnol. 28, 436–440 (2010).

  10. 10

    Hanley, J.A. & NcNeil, B.J. Radiology 143, 29–36 (1982).

  11. 11

    The Food and Drug Administration Biomarker Qualification Review Team. Review of Qualification Data for Biomarkers of Nephrotoxicity Submitted by the Predictive Safety Testing Consortium (FDA CDER, 21 February 2008).

  12. 12

    EMEA. Biomarkers Qualification: Guidance to Applicants (doc. ref. EMEA/CHMP/SAWP/72894/2008-CONSULTATION, 24 April 2008).

Download references

Author information

Correspondence to David G Warnock or Carl C Peck.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Warnock, D., Peck, C. A roadmap for biomarker qualification. Nat Biotechnol 28, 444–445 (2010) doi:10.1038/nbt0510-444

Download citation

Further reading